Clinical value of ALK and CD30 expression in mature systemic T
cell lymphomas: analysis from the Czech Lymphoma Study Group
database (NIHIL)

J 2022

Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL)

JANÍKOVÁ, Andrea, Jozef MICHALKA, Renata CHLOUPKOVÁ, Natasa KOPALOVA, V. CAMPR et. al.

Basic information

Original name

Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL)

Authors

JANÍKOVÁ, Andrea (203 Czech Republic, guarantor, belonging to the institution), Jozef MICHALKA (703 Slovakia, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Natasa KOPALOVA (203 Czech Republic), V. CAMPR (203 Czech Republic), K. KAMARADOVA (203 Czech Republic), Leoš KŘEN (203 Czech Republic, belonging to the institution), D. BELADA (203 Czech Republic), K. BENESOVA (203 Czech Republic), J. DLOUHA, P. KLENER, V. PROCHÁZKA, H. MOCIKOVA (203 Czech Republic), J. DURAS (203 Czech Republic) and M. TRNENY (203 Czech Republic)

Edition

Annals of hematology, New York, Springer Verlag, 2022, 0939-5555

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.500

RIV identification code

RIV/00216224:14110/22:00126151

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s00277-022-04759-1

UT WoS

000745380700001

Keywords in English

Peripheral T cell lymphoma; CD30; ALK; Prognosis

Abstract

V originále

Mature T cell lymphomas (MTCLs) have worse prognosis, and in contrast to B cell lymphomas, there is no universal marker like CD20 with exception of ALK and CD30, which are present in proportion of MTCL only. Up to now, ALK is traditionally associated with good prognosis in ALCLs, and there are some evidences that CD30-positive T cell or B cell lymphomas have better prognosis. In our retrospective, population-based analysis, we analyzed the real clinical value of ALK and CD30 in the most frequent MTCL subtypes. Between 2000 and 2017, we identified 732 patients with newly diagnosed ALCL, AITL, or PTCL-NOS. Among them, 207 ALCL patients were with known ALK, whereas 61 AITL and 238 PTCL-NOS with known CD30 expression. There were 69/207 (33.3%) ALK + ALCLs, who displayed better 5-year PFS (65.6% vs. 36.2%) (p .001) and 5-year OS (71.5% vs. 45.9%) (p .002) compared to ALK -; ALK + patients were significantly younger (median 48 vs. 60 years; p < 0.001). For patients >= 60 years, 5-year PFS (38.5% vs. 31.2%) and 5-year OS (38.5% vs. 39.6%) were similar between ALK + vs. ALK - patients. For AITL and PTCL-NOS, there were 44/61 (72.1%) and 120/238 (50.4%) CD30 + samples, and difference in CD30 expression was significant (p .02). AITL patients had 5-year OS of 43.8% vs. 55.7% (p 0.848) and 5-year PFS of 36.7% vs. 29.4% (p .624) for CD30 + vs. CD30 - patients, whereas PTCL-NOS had 5-year OS of 35.7% vs. 34.3% (p .318) and 5-year PFS of 29.3% vs. 22.5% (p .114) for CD30 + vs. CD30 - cases. We conclude that ALK in ALCLs (>= 60 years) and CD30 expression in PCTL-NOS and AITL have only limited prognostic value.

Citovat

JANÍKOVÁ, Andrea, Jozef MICHALKA, Renata CHLOUPKOVÁ, Natasa KOPALOVA, V. CAMPR, K. KAMARADOVA, Leoš KŘEN, D. BELADA, K. BENESOVA, J. DLOUHA, P. KLENER, V. PROCHÁZKA, H. MOCIKOVA, J. DURAS and M. TRNENY. Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL). Annals of hematology. New York: Springer Verlag, 2022, vol. 101, No 4, p. 789-798. ISSN 0939-5555. Available from: https://dx.doi.org/10.1007/s00277-022-04759-1.

@article{1863085,
   author = {Janíková, Andrea and Michalka, Jozef and Chloupková, Renata and Kopalova, Natasa and Campr, V. and Kamaradova, K. and Křen, Leoš and Belada, D. and Benesova, K. and Dlouha, J. and Klener, P. and Procházka, V. and Mocikova, H. and Duras, J. and Trneny, M.},
   article_location = {New York},
   article_number = {4},
   doi = {http://dx.doi.org/10.1007/s00277-022-04759-1},
   keywords = {Peripheral T cell lymphoma; CD30; ALK; Prognosis},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of hematology},
   title = {Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL)},
   url = {https://link.springer.com/article/10.1007/s00277-022-04759-1},
   volume = {101},
   year = {2022}
}

TY  - JOUR
ID  - 1863085
AU  - Janíková, Andrea - Michalka, Jozef - Chloupková, Renata - Kopalova, Natasa - Campr, V. - Kamaradova, K. - Křen, Leoš - Belada, D. - Benesova, K. - Dlouha, J. - Klener, P. - Procházka, V. - Mocikova, H. - Duras, J. - Trneny, M.
PY  - 2022
TI  - Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL)
JF  - Annals of hematology
VL  - 101
IS  - 4
SP  - 789-798
EP  - 789-798
PB  - Springer Verlag
SN  - 09395555
KW  - Peripheral T cell lymphoma
KW  - CD30
KW  - ALK
KW  - Prognosis
UR  - https://link.springer.com/article/10.1007/s00277-022-04759-1
N2  - Mature T cell lymphomas (MTCLs) have worse prognosis, and in contrast to B cell lymphomas, there is no universal marker like CD20 with exception of ALK and CD30, which are present in proportion of MTCL only. Up to now, ALK is traditionally associated with good prognosis in ALCLs, and there are some evidences that CD30-positive T cell or B cell lymphomas have better prognosis. In our retrospective, population-based analysis, we analyzed the real clinical value of ALK and CD30 in the most frequent MTCL subtypes. Between 2000 and 2017, we identified 732 patients with newly diagnosed ALCL, AITL, or PTCL-NOS. Among them, 207 ALCL patients were with known ALK, whereas 61 AITL and 238 PTCL-NOS with known CD30 expression. There were 69/207 (33.3%) ALK + ALCLs, who displayed better 5-year PFS (65.6% vs. 36.2%) (p .001) and 5-year OS (71.5% vs. 45.9%) (p .002) compared to ALK -; ALK + patients were significantly younger (median 48 vs. 60 years; p < 0.001). For patients >= 60 years, 5-year PFS (38.5% vs. 31.2%) and 5-year OS (38.5% vs. 39.6%) were similar between ALK + vs. ALK - patients. For AITL and PTCL-NOS, there were 44/61 (72.1%) and 120/238 (50.4%) CD30 + samples, and difference in CD30 expression was significant (p .02). AITL patients had 5-year OS of 43.8% vs. 55.7% (p 0.848) and 5-year PFS of 36.7% vs. 29.4% (p .624) for CD30 + vs. CD30 - patients, whereas PTCL-NOS had 5-year OS of 35.7% vs. 34.3% (p .318) and 5-year PFS of 29.3% vs. 22.5% (p .114) for CD30 + vs. CD30 - cases. We conclude that ALK in ALCLs (>= 60 years) and CD30 expression in PCTL-NOS and AITL have only limited prognostic value.
ER  -

JANÍKOVÁ, Andrea, Jozef MICHALKA, Renata CHLOUPKOVÁ, Natasa KOPALOVA, V. CAMPR, K. KAMARADOVA, Leoš KŘEN, D. BELADA, K. BENESOVA, J. DLOUHA, P. KLENER, V. PROCHÁZKA, H. MOCIKOVA, J. DURAS and M. TRNENY. Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL). \textit{Annals of hematology}. New York: Springer Verlag, 2022, vol.~101, No~4, p.~789-798. ISSN~0939-5555. Available from: https://dx.doi.org/10.1007/s00277-022-04759-1.

Detailed Information on Publication Record